You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.

DrugBank Version 4.3

The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with comprehensive drug target (i.e. sequence, structure, and pathway) information. The database contains 7759 drug entries including 1602 FDA-approved small molecule drugs, 161 FDA-approved biotech (protein/peptide) drugs, 89 nutraceuticals and over 6000 experimental drugs. Additionally, 4300 non-redundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked to these drug entries. Each DrugCard entry contains more than 200 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data. More about DrugBank

Drug of the day: Atomoxetine


Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]

For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.

Learn more about Atomoxetine

Recent Comments

DrugBank is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (DrugBank) and the original publication (see below). We ask that users who download significant portions of the database cite the DrugBank paper in any resulting publications.

Please cite:

  1. DrugBank 4.0: shedding new light on drug metabolism.Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS.Nucleic Acids Res. 2014 Jan 1;42(1):D1091-7.
    PubMed ID: 24203711
  2. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
    PubMed ID: 21059682
  3. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M.Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
    PubMed ID: 18048412
  4. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J.Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72.
    PubMed ID: 16381955